MedTrace Logo

Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia

NCT01310010 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-03-17

No results posted yet for this study

Summary

Study hypothesis:

Treatment with dasatinib 100 mg QD is safe and efficacious when given to patients with Ph+ ALL in the post SCT setting.

Conditions

  • Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Interventions

DRUG

dasatinib

Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).

Sponsors & Collaborators

  • Grupo Espanol de trasplantes hematopoyeticos y terapia celular

    lead OTHER

Principal Investigators

  • Guillermo Sanz, Doctor · Hospital La Fe de Valencia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2015-10-31
Completion
2016-07-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01310010 on ClinicalTrials.gov